Targeting of the CD161 inhibitory receptor enhances T-cell-mediated immunity against hematological malignancies.
Alvarez Calderon F, Kang BH, Kyrysyuk O, Zheng S, Wang H, Mathewson ND, Luoma AM, Ning X, Pyrdol J, Cao X, Suvà ML, Yuan GC, Wittrup KD, Wucherpfennig KW.
Alvarez Calderon F, et al. Among authors: wucherpfennig kw.
Blood. 2024 Mar 21;143(12):1124-1138. doi: 10.1182/blood.2023022882.
Blood. 2024.
PMID: 38153903